Streetbeat News

Regulatory

TELO

Telomir Pharmaceuticals announced pre-clinical data for its age-reversal drug, Telomir-1, showing a 40% increase in telomerase activity and lengthened telomeres in human cells. The company provided endpoints for assessing the drug's effects in dogs and outlined plans for human and animal IND trials targeting osteoarthritis.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:39 pm

BRTX

CGEM

ITCI

Cullinan Therapeutics (CGEM) shifts focus to autoimmune diseases, discontinuing its B-NHL study to develop CLN-978, with lupus as the first target. Intra-Cellular (ITCI) reports positive Phase 3 results for Lumateperone in major depressive disorder. BioRestorative Therapies (BRTX) sees shares rise after FDA clearance for a Phase 2 study protocol amendment.

Portfolio Pulse from ryanfaloona@benzinga.com

April 16, 2024 | 12:36 pm

SPY

The Building Permits (MoM) for March showed a decrease of 4.3%, indicating a slowdown in the construction sector. This data could have implications for the broader economy and potentially affect market sentiment.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:30 pm

SPY

US Building Permits for March reported at 1.458M, falling short of the estimated 1.514M and the previous month's 1.523M.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:30 pm

TEVA

Teva Pharmaceuticals announced positive final results from the Phase 4 START study of AUSTEDO's 4-week Titration Kit for Huntington's disease (HD) chorea at the 2024 AAN Annual Meeting. The study showed that nearly 80% of patients achieved optimal dosing within four weeks, with significant improvements in symptoms and high patient satisfaction. AUSTEDO is highlighted as the only VMAT2 inhibitor with 3-year data for HD chorea, emphasizing its real-world effectiveness, safety, and adherence.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:18 pm

MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced the filing of a provisional patent for advancements in its MNPR-101 radiopharmaceutical program, aimed at developing treatments for advanced cancers. The patent covers the MNPR-101-Zr construct, including variations that could enhance its clinical profile. This move is expected to strengthen Monopar's intellectual property around the MNPR-101 program, which is currently in a Phase 1 dosimetry clinical trial for patients with advanced cancers.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:05 pm

BRTX

BioRestorative Therapies' stock price increased following the FDA's approval of a protocol amendment for its Phase 2 BRTX-100 clinical study. This regulatory milestone is significant for the company's progress in developing its therapies.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:58 am

ENLV

Enlivex has received authorization from the Danish Medicines Agency for a Phase I/II trial to evaluate Allocetra in treating knee osteoarthritis. This marks a significant step forward in the development of Allocetra, potentially opening new treatment avenues for patients with this condition.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:57 am

AMD

FTXL

INTC

NVDA

SOXQ

Intel and Nvidia are adapting their AI chip strategies for the Chinese market in response to U.S. sanctions by launching China-specific products with reduced capabilities. Intel plans to release two AI chips, HL-328 and HL-388, while Nvidia is developing three China-specific chips. These moves come as both companies face challenges in China due to the country's push to remove foreign technology from its telecom networks by 2027. Intel's stock has seen a 13% increase over the last 12 months, and its performance can also impact related ETFs like FTXL and SOXQ.

Portfolio Pulse from Anusuya Lahiri

April 16, 2024 | 11:47 am